SG11201605919YA - Agents for use in the treatment of retinal inflammation - Google Patents

Agents for use in the treatment of retinal inflammation

Info

Publication number
SG11201605919YA
SG11201605919YA SG11201605919YA SG11201605919YA SG11201605919YA SG 11201605919Y A SG11201605919Y A SG 11201605919YA SG 11201605919Y A SG11201605919Y A SG 11201605919YA SG 11201605919Y A SG11201605919Y A SG 11201605919YA SG 11201605919Y A SG11201605919Y A SG 11201605919YA
Authority
SG
Singapore
Prior art keywords
agents
treatment
retinal inflammation
retinal
inflammation
Prior art date
Application number
SG11201605919YA
Inventor
Florian Sennlaub
Xavier Guillonneau
Olivier Levy
José-Alain Sahel
Original Assignee
Université Pierre Et Marie Curie Paris 6 Upmc
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49998095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201605919Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Pierre Et Marie Curie Paris 6 Upmc, Centre Nat Rech Scient filed Critical Université Pierre Et Marie Curie Paris 6 Upmc
Publication of SG11201605919YA publication Critical patent/SG11201605919YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201605919YA 2014-01-22 2015-01-22 Agents for use in the treatment of retinal inflammation SG11201605919YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14152189.8A EP2898896A1 (en) 2014-01-22 2014-01-22 Agents for use in the treatment of retinal inflammation
PCT/EP2015/051293 WO2015110556A1 (en) 2014-01-22 2015-01-22 Agents for use in the treatment of retinal inflammation

Publications (1)

Publication Number Publication Date
SG11201605919YA true SG11201605919YA (en) 2016-08-30

Family

ID=49998095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605919YA SG11201605919YA (en) 2014-01-22 2015-01-22 Agents for use in the treatment of retinal inflammation

Country Status (12)

Country Link
US (1) US10519232B2 (en)
EP (2) EP2898896A1 (en)
JP (1) JP6689484B2 (en)
KR (1) KR102379006B1 (en)
AU (1) AU2015208105A1 (en)
BR (1) BR112016016901A2 (en)
CA (1) CA2937591C (en)
IL (1) IL246855A0 (en)
MX (1) MX2016009600A (en)
RU (1) RU2016133022A (en)
SG (1) SG11201605919YA (en)
WO (1) WO2015110556A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009553A1 (en) 2015-12-23 2017-06-29 Centre National De La Recherche Scientifique Agents that inhibit the binding of cfh to cd11b/cd18 and uses thereof
ITUB20169937A1 (en) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF PIGMENTAL RETINITIS
KR20180116359A (en) 2016-02-23 2018-10-24 세센 바이오, 아이엔씨. Antagonist formulations of interleukin-6 and uses thereof
JP7537074B2 (en) * 2016-05-10 2024-08-21 ソルボンヌ ウニベルシテ Agents that activate CD47 and their use in treating inflammation - Patents.com
CN116710135A (en) * 2020-10-07 2023-09-05 6线生物技术公司 Methods and agents for treating ocular disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2914672B2 (en) 1989-01-17 1999-07-05 中外製薬株式会社 BSF (2) Antagonist
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
RU2139351C1 (en) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся H- and l-chains of monoclonal antibody pm-1 (monat) to human il-6r receptor and their v-region, modified monat, its h- and l-chains and their v-regions, cdr-sequence, dna-sequence
JPH07324097A (en) 1994-05-30 1995-12-12 Daicel Chem Ind Ltd Interleukin 6 antagonist, peptides or pharmaceutically permissible salts thereof
IT1274350B (en) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio INTERLEUCHINA-6 (IL-6) ANTAGONISTS, WHICH CONSIST OF SOLUBLE FORMS OF THE ALFA RECEPTOR OF IL-6, CHANGED IN THE INTERFACE THAT LINKS TO GP 130
IT1274782B (en) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130
JPH08311098A (en) 1995-05-22 1996-11-26 Daicel Chem Ind Ltd New peptides and interleukin 6 antagonistic agent containing the peptide
US6001962A (en) 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
WO1999065935A2 (en) 1998-06-18 1999-12-23 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
WO2004045507A2 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
DK2116530T3 (en) * 2007-02-26 2013-01-28 Santen Pharmaceutical Co Ltd New pyrrole derivative having a ureide group and an aminobonyl group as substituents
JP5424330B2 (en) * 2007-07-26 2014-02-26 国立大学法人大阪大学 A therapeutic agent for ocular inflammatory diseases comprising an interleukin 6 receptor inhibitor as an active ingredient
US20090082470A1 (en) 2007-09-24 2009-03-26 Rafal Farjo Stat3 inhibiting compositions and methods
US8088817B2 (en) * 2008-08-25 2012-01-03 Santen Pharmaceutical Co., Ltd. Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent
TWI719277B (en) * 2011-11-14 2021-02-21 美商安斯泰來再生醫藥協會 Pharmaceutical preparations of human rpe cells and uses thereof
WO2013148183A2 (en) 2012-03-28 2013-10-03 Regenerative Research Foundatoin Compositions and methods for inhibiting drusen
NZ706377A (en) * 2012-11-08 2019-06-28 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof

Also Published As

Publication number Publication date
WO2015110556A1 (en) 2015-07-30
JP6689484B2 (en) 2020-04-28
US20160340424A1 (en) 2016-11-24
AU2015208105A1 (en) 2016-08-04
EP3096781B1 (en) 2022-11-02
KR102379006B1 (en) 2022-03-28
CA2937591A1 (en) 2015-07-30
CA2937591C (en) 2022-09-06
EP3096781A1 (en) 2016-11-30
MX2016009600A (en) 2017-02-13
RU2016133022A (en) 2018-02-26
IL246855A0 (en) 2016-08-31
KR20160106667A (en) 2016-09-12
EP2898896A1 (en) 2015-07-29
US10519232B2 (en) 2019-12-31
BR112016016901A2 (en) 2018-03-20
JP2017505303A (en) 2017-02-16

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
PL3157512T3 (en) Use of cannabidiol in the treatment of epilepsy
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumours
IL247589A0 (en) Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
PL3277280T3 (en) Isomyosmine for use in the treatment of autoimmune diseases
IL251904A0 (en) Apilimod for use in the treatment of melanoma
IL247969B (en) A therapeutic agent for use in the treatment of infections
HK1256164A1 (en) Agents for use in the treatment of glioma
IL246855A0 (en) Agents for use in the treatment of retinal inflammation
HUE039750T2 (en) 6-hydroxybuspirone for use in the treatment of movement disorders
HK1252811A1 (en) Compounds for use in the treatment of androgen deprivation therapy associated symptoms